TY  - GEN
AU  - Maemondo,Makoto
AU  - Minegishi,Yuji
AU  - Inoue,Akira
AU  - Kobayashi,Kunihiko
AU  - Harada,Masao
AU  - Okinaga,Shoji
AU  - Morikawa,Naoto
AU  - Oizumi,Satoshi
AU  - Tanaka,Tomoaki
AU  - Isobe,Hiroshi
AU  - Kudoh,Shoji
AU  - Hagiwara,Koichi
AU  - Nukiwa,Toshihiro
AU  - Gemma,Akihiko
AU  - Gemmah,Akihiko
TI  - First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study
SN  - 1556-1380
PY  - 2013///0117
KW  - Adenocarcinoma
KW  - drug therapy
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Agents
KW  - therapeutic use
KW  - Carcinoma, Adenosquamous
KW  - Carcinoma, Non-Small-Cell Lung
KW  - ErbB Receptors
KW  - antagonists & inhibitors
KW  - Feasibility Studies
KW  - Female
KW  - Follow-Up Studies
KW  - Gefitinib
KW  - Humans
KW  - Lung Neoplasms
KW  - Male
KW  - Mutation
KW  - genetics
KW  - Neoplasm Staging
KW  - Prognosis
KW  - Quinazolines
KW  - Survival Rate
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1097/JTO.0b013e318260de8b
ER  -